Skip to content
2000
image of Melatonin: Novel Insights in the Treatment of Neurodegenerative Diseases

Abstract

Melatonin, a hormone primarily synthesized by the pineal gland and known for regulating sleep-wake cycles, has emerged as a promising therapeutic agent in neurodegenerative diseases. Recent research has uncovered novel insights into melatonin's neuroprotective effects, including its ability to modulate mitochondrial function, enhance autophagy, and regulate epigenetic mechanisms, offering new therapeutic avenues. This review summarizes current knowledge, novel mechanisms, and future research directions of melatonin in neurodegenerative diseases. This review synthesizes evidence from clinical trials and preclinical research published between 1960 and March 2025, sourced from PubMed, Scopus, Google Scholar, and the Cochrane Library. Findings highlight melatonin's potent antioxidant and anti-inflammatory properties, which mitigate oxidative stress, reduce neuroinflammation, and promote neuronal survival. Additionally, melatonin supplementation has shown promise in improving sleep disturbances, cognitive function, and quality of life in neurodegenerative diseases. Emerging evidence also suggests synergistic effects of melatonin with other neuroprotective agents and its potential in early-stage disease intervention. Despite these advances, challenges remain, including optimizing dosing regimens and understanding long-term effects. By integrating preclinical and clinical insights, this review underscores melatonin's potential as a multifaceted therapeutic agent in neurodegenerative diseases.

© 202 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673416300251023052701
2026-02-23
2026-03-02

  • From This Site

    /content/journals/cmc/10.2174/0109298673416300251023052701
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Lamptey R.N.L. Chaulagain B. Trivedi R. Gothwal A. Layek B. Singh J. A review of the common neurodegenerative disorders: Current therapeutic approaches and the potential role of nanotherapeutics. Int. J. Mol. Sci. 2022 23 3 1851 10.3390/ijms23031851 35163773
    [Google Scholar]
  2. Gunata M. Parlakpinar H. Acet H.A. Melatonin: A review of its potential functions and effects on neurological diseases. Rev. Neurol. 2020 176 3 148 165 10.1016/j.neurol.2019.07.025 31718830
    [Google Scholar]
  3. Bantounou M. Plascevic J. Galley H.F. Melatonin and related compounds: Antioxidant and anti-inflammatory actions. Antioxidants 2022 11 3 532 10.3390/antiox11030532
    [Google Scholar]
  4. Ahmad S.B. Ali A. Bilal M. Rashid S.M. Wani A.B. Bhat R.R. Rehman M.U. Melatonin and health: Insights of melatonin action, biological functions, and associated disorders. Cell. Mol. Neurobiol. 2023 43 6 2437 2458 10.1007/s10571‑023‑01324‑w 36752886
    [Google Scholar]
  5. Sadanandan N. Cozene B. Cho J. Park Y.J. Saft M. Gonzales-Portillo B. Borlongan C.V. Melatonin—a potent therapeutic for stroke and stroke-related dementia. Antioxidants 2020 9 8 672 10.3390/antiox9080672 32731545
    [Google Scholar]
  6. Tozihi M. Shademan B. Yousefi H. Avci C.B. Nourazarian A. Dehghan G. Melatonin: A promising neuroprotective agent for cerebral ischemia-reperfusion injury. Front. Aging Neurosci. 2023 15 1227513 10.3389/fnagi.2023.1227513 37600520
    [Google Scholar]
  7. Shin J.W. Neuroprotective effects of melatonin in neurodegenerative and autoimmune central nervous system diseases. Encephalitis 2023 3 2 44 53 10.47936/encephalitis.2022.00094 37469673
    [Google Scholar]
  8. Loren P. Sánchez R. Arias M.E. Felmer R. Risopatrón J. Cheuquemán C. Melatonin scavenger properties against oxidative and nitrosative stress: Impact on gamete handling and in vitro embryo production in humans and other mammals. Int. J. Mol. Sci. 2017 18 6 1119 10.3390/ijms18061119 28613231
    [Google Scholar]
  9. Zhang H.M. Zhang Y. Melatonin: A well-documented antioxidant with conditional pro-oxidant actions. J. Pineal Res. 2014 57 2 131 146 10.1111/jpi.12162 25060102
    [Google Scholar]
  10. Favero G. Franceschetti L. Bonomini F. Rodella L.F. Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int. J. Endocrinol. 2017 2017 1 13 10.1155/2017/1835195 29104591
    [Google Scholar]
  11. Hardeland R. Melatonin and inflammation—Story of a double-edged blade. J. Pineal Res. 2018 65 4 12525 10.1111/jpi.12525 30242884
    [Google Scholar]
  12. Amor S. Puentes F. Baker D. Van Der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010 129 2 154 169 10.1111/j.1365‑2567.2009.03225.x 20561356
    [Google Scholar]
  13. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009 15 4 345 357 10.1111/j.1755‑5949.2009.00105.x 19818070
    [Google Scholar]
  14. Brettschneider J. Arai K. Del Tredici K. Toledo J.B. Robinson J.L. Lee E.B. Kuwabara S. Shibuya K. Irwin D.J. Fang L. Van Deerlin V.M. Elman L. McCluskey L. Ludolph A.C. Lee V.M.Y. Braak H. Trojanowski J.Q. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathol. 2014 128 3 423 437 10.1007/s00401‑014‑1299‑6 24916269
    [Google Scholar]
  15. Guo Z. Rudow G. Pletnikova O. Codispoti K.E. Orr B.A. Crain B.J. Duan W. Margolis R.L. Rosenblatt A. Ross C.A. Troncoso J.C. Striatal neuronal loss correlates with clinical motor impairment in Huntington’s disease. Mov. Disord. 2012 27 11 1379 1386 10.1002/mds.25159 22975850
    [Google Scholar]
  16. Chi H. Chang H.Y. Sang T.K. Neuronal cell death mechanisms in major neurodegenerative diseases. Int. J. Mol. Sci. 2018 19 10 3082 10.3390/ijms19103082 30304824
    [Google Scholar]
  17. Gitler A.D. Dhillon P. Shorter J. Neurodegenerative disease: Models, mechanisms, and a new hope. Dis. Model. Mech. 2017 10 5 499 502 10.1242/dmm.030205 28468935
    [Google Scholar]
  18. Armstrong R. What causes neurodegenerative disease? Folia. Neuropathol. 2020 58 2 93 112 10.5114/fn.2020.96707 32729289
    [Google Scholar]
  19. Abdolmaleky H. Zhou J.R. Underlying mechanisms of brain aging and neurodegenerative diseases as potential targets for preventive or therapeutic strategies using phytochemicals. Nutrients 2023 15 15 3456 10.3390/nu15153456 37571393
    [Google Scholar]
  20. Song T. Song X. Zhu C. Patrick R. Skurla M. Santangelo I. Green M. Harper D. Ren B. Forester B.P. Öngür D. Du F. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res. Rev. 2021 72 101503 10.1016/j.arr.2021.101503 34751136
    [Google Scholar]
  21. Lassmann H. Bancher C. Breitschopf H. Wegiel J. Bobinski M. Jellinger K. Wisniewski H.M. Cell death in Alzheimer’s disease evaluated by DNA fragmentation in situ. Acta Neuropathol. 1995 89 1 35 41 10.1007/BF00294257 7709729
    [Google Scholar]
  22. Ittner A. Chua S.W. Bertz J. Volkerling A. van der Hoven J. Gladbach A. Przybyla M. Bi M. van Hummel A. Stevens C.H. Ippati S. Suh L.S. Macmillan A. Sutherland G. Kril J.J. Silva A.P.G. Mackay J.P. Poljak A. Delerue F. Ke Y.D. Ittner L.M. Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice. Science 2016 354 6314 904 908 10.1126/science.aah6205 27856911
    [Google Scholar]
  23. Alifragis P. Marsh J. Synaptic dysfunction in Alzheimer’s disease: The effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. Neural Regen. Res. 2018 13 4 616 623 10.4103/1673‑5374.230276 29722304
    [Google Scholar]
  24. Bano D. Ankarcrona M. Beyond the critical point: An overview of excitotoxicity, calcium overload and the downstream consequences. Neurosci. Lett. 2018 663 79 85 10.1016/j.neulet.2017.08.048 28843346
    [Google Scholar]
  25. Ittner L.M. Ke Y.D. Delerue F. Bi M. Gladbach A. van Eersel J. Wölfing H. Chieng B.C. Christie M.J. Napier I.A. Eckert A. Staufenbiel M. Hardeman E. Götz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 2010 142 3 387 397 10.1016/j.cell.2010.06.036 20655099
    [Google Scholar]
  26. Zhou L. Chen D. Huang X.M. Long F. Cai H. Yao W.X. Chen Z.C. Liao Z.J. Deng Z.Z. Tan S. Shan Y.L. Cai W. Wang Y.G. Yang R.H. Jiang N. Peng T. Hong M.F. Lu Z.Q. Wnt5a promotes cortical neuron survival by inhibiting cell-cycle activation. Front. Cell. Neurosci. 2017 11 281 10.3389/fncel.2017.00281 29033786
    [Google Scholar]
  27. Caccamo A. Branca C. Piras I.S. Ferreira E. Huentelman M.J. Liang W.S. Readhead B. Dudley J.T. Spangenberg E.E. Green K.N. Belfiore R. Winslow W. Oddo S. Necroptosis activation in Alzheimer’s disease. Nat. Neurosci. 2017 20 9 1236 1246 10.1038/nn.4608 28758999
    [Google Scholar]
  28. Ross G.W. Petrovitch H. Abbott R.D. Nelson J. Markesbery W. Davis D. Hardman J. Launer L. Masaki K. Tanner C.M. White L.R. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann. Neurol. 2004 56 4 532 539 10.1002/ana.20226 15389895
    [Google Scholar]
  29. Degterev A. Hitomi J. Germscheid M. Ch’en I.L. Korkina O. Teng X. Abbott D. Cuny G.D. Yuan C. Wagner G. Hedrick S.M. Gerber S.A. Lugovskoy A. Yuan J. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008 4 5 313 321 10.1038/nchembio.83 18408713
    [Google Scholar]
  30. Iannielli A. Bido S. Folladori L. Segnali A. Cancellieri C. Maresca A. Massimino L. Rubio A. Morabito G. Caporali L. Tagliavini F. Musumeci O. Gregato G. Bezard E. Carelli V. Tiranti V. Broccoli V. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in parkinson’s disease models. Cell Rep. 2018 22 8 2066 2079 10.1016/j.celrep.2018.01.089 29466734
    [Google Scholar]
  31. Alqahtani T. Deore S.L. Kide A.A. Shende B.A. Sharma R. Dadarao Chakole R. Nemade L.S. Kishor Kale N. Borah S. Shrikant Deokar S. Behera A. Dhawal Bhandari D. Gaikwad N. Kalam Azad A. Ghosh A. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease, and Parkinson’s disease, Huntington’s disease and Amyotrophic Lateral Sclerosis -An updated review. Mitochondrion 2023 71 83 92 10.1016/j.mito.2023.05.007 37269968
    [Google Scholar]
  32. Freeman D. Cedillos R. Choyke S. Lukic Z. McGuire K. Marvin S. Burrage A.M. Sudholt S. Rana A. O’Connor C. Wiethoff C.M. Campbell E.M. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS One 2013 8 4 62143 10.1371/journal.pone.0062143 23634225
    [Google Scholar]
  33. Bonafede R. Mariotti R. ALS pathogenesis and therapeutic approaches: The role of mesenchymal stem cells and extracellular vesicles. Front. Cell. Neurosci. 2017 11 80 10.3389/fncel.2017.00080 28377696
    [Google Scholar]
  34. Re D.B. Le Verche V. Yu C. Amoroso M.W. Politi K.A. Phani S. Ikiz B. Hoffmann L. Koolen M. Nagata T. Papadimitriou D. Nagy P. Mitsumoto H. Kariya S. Wichterle H. Henderson C.E. Przedborski S. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014 81 5 1001 1008 10.1016/j.neuron.2014.01.011 24508385
    [Google Scholar]
  35. Xiong L. McCoy M. Komuro H. West X.Z. Yakubenko V. Gao D. Dudiki T. Milo A. Chen J. Podrez E.A. Trapp B. Byzova T.V. Inflammation-dependent oxidative stress metabolites as a hallmark of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2022 178 125 133 10.1016/j.freeradbiomed.2021.11.031 34871763
    [Google Scholar]
  36. Compston A. Coles A. Multiple sclerosis. Lancet 2008 372 9648 1502 1517 10.1016/S0140‑6736(08)61620‑7 18970977
    [Google Scholar]
  37. Pegoretti V. Swanson K.A. Bethea J.R. Probert L. Eisel U.L.M. Fischer R. Inflammation and oxidative stress in multiple sclerosis: Consequences for therapy development. Oxid. Med. Cell. Longev. 2020 2020 1 19 10.1155/2020/7191080 32454942
    [Google Scholar]
  38. Hanisch U.K. Kettenmann H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007 10 11 1387 1394 10.1038/nn1997 17965659
    [Google Scholar]
  39. Lin C.C. Edelson B.T. New insights into the role of IL-1β in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Immunol. 2017 198 12 4553 4560 10.4049/jimmunol.1700263
    [Google Scholar]
  40. Adamczyk-Sowa M. Galiniak S. Żyracka E. Grzesik M. Naparło K. Sowa P. Bartosz G. Sadowska-Bartosz I. Oxidative modification of blood serum proteins in multiple sclerosis after interferon beta and melatonin treatment. Oxid. Med. Cell. Longev. 2017 2017 1 7905148 10.1155/2017/7905148 29181127
    [Google Scholar]
  41. Ambrozaitis K.V. Kontautas E. Spakauskas B. Vaitkaitis D. [Pathophysiology of acute spinal cord injury]. Medicina 2006 42 3 255 261 16607070
    [Google Scholar]
  42. Quadri S.A. Farooqui M. Ikram A. Zafar A. Khan M.A. Suriya S.S. Claus C.F. Fiani B. Rahman M. Ramachandran A. Armstrong I.I.T. Taqi M.A. Mortazavi M.M. Recent update on basic mechanisms of spinal cord injury. Neurosurg. Rev. 2020 43 2 425 441 10.1007/s10143‑018‑1008‑3 29998371
    [Google Scholar]
  43. Borgens R.B. Liu-Snyder P. Understanding secondary injury. Q. Rev. Biol. 2012 87 2 89 127 10.1086/665457 22696939
    [Google Scholar]
  44. Oyinbo C. Secondary injury mechanisms in traumatic spinal cord injury: A nugget of this multiply cascade. Acta Neurobiol. Exp. 2011 71 2 281 299 10.55782/ane‑2011‑1848 21731081
    [Google Scholar]
  45. Zhang H. Trivedi A. Lee J.U. Lohela M. Lee S.M. Fandel T.M. Werb Z. Noble-Haeusslein L.J. Matrix metalloproteinase-9 and stromal cell-derived factor-1 act synergistically to support migration of blood-borne monocytes into the injured spinal cord. J. Neurosci. 2011 31 44 15894 15903 10.1523/JNEUROSCI.3943‑11.2011 22049432
    [Google Scholar]
  46. Leister I. Altendorfer B. Maier D. Mach O. Wutte C. Grillhösl A. Arevalo-Martin A. Garcia-Ovejero D. Aigner L. Grassner L. Trajectory of serum levels of glial fibrillary acidic protein within four weeks post-injury is related to neurological recovery during the transition from acute to chronic spinal cord injury. J. Neurotrauma 2023 40 9-10 999 1006 10.1089/neu.2022.0326 36200629
    [Google Scholar]
  47. Ohtake Y. Li S. Molecular mechanisms of scar-sourced axon growth inhibitors. Brain Res. 2015 1619 22 35 10.1016/j.brainres.2014.08.064 25192646
    [Google Scholar]
  48. Kofod J. Elfving B. Nielsen E.H. Mors O. Köhler-Forsberg O. Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. Eur. Neuropsychopharmacol. 2022 54 116 125 10.1016/j.euroneuro.2021.09.006
    [Google Scholar]
  49. Lamtai M. Zghari O. Azirar S. Ouakki S. Mesfioui A. EL Hessni A. Berkiks I. Marmouzi I. Ouichou A. Melatonin modulates copper-induced anxiety-like, depression-like and memory impairments by acting on hippocampal oxidative stress in rat. Drug Chem. Toxicol. 2022 45 4 1707 1715 10.1080/01480545.2020.1858853 33412940
    [Google Scholar]
  50. Troubat R. Barone P. Leman S. Desmidt T. Cressant A. Atanasova B. Brizard B. El Hage W. Surget A. Belzung C. Camus V. Neuroinflammation and depression: A review. Eur. J. Neurosci. 2021 53 1 151 171 10.1111/ejn.14720 32150310
    [Google Scholar]
  51. Escribano B Colin-Gonzalez LA Santamaría A Túnez I The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. CNS Neurol. Disord. Drug Targets 2014 13 6 1096 1119
    [Google Scholar]
  52. Nabavi S.M. Nabavi S.F. Sureda A. Xiao J. Dehpour A.R. Shirooie S. Silva A.S. Baldi A. Khan H. Daglia M. Anti-inflammatory effects of Melatonin: A mechanistic review. Crit. Rev. Food Sci. Nutr. 2019 59 sup1 S4 S16 10.1080/10408398.2018.1487927
    [Google Scholar]
  53. Arias J. Melean E. Valero N. Pons H. Chacín-Bonilla L. Larreal Y. Bonilla E. [Effect of melatonin on lymphocyte proliferation and production of interleukin-2 (IL-2) and interleukin-1 beta (IL-1 beta) in mice splenocytes]. Invest. Clin. 2003 44 1 41 50 12703182
    [Google Scholar]
  54. Garcia-Mauriño S. Gonzalez-Haba M.G. Calvo J.R. Rafii-El-Idrissi M. Sanchez-Margalet V. Goberna R. Guerrero J.M. Melatonin enhances IL-2, IL-6, and IFN-γ production by human circulating CD4+ cells: A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 1997 159 2 574 581 10.4049/jimmunol.159.2.574
    [Google Scholar]
  55. Kaur C. Ling E.A. Effects of melatonin on macrophages/microglia in postnatal rat brain. J. Pineal Res. 1999 26 3 158 168 10.1111/j.1600‑079X.1999.tb00578.x 10231729
    [Google Scholar]
  56. Lissoni P. Marelli O. Mauri R. Resentini M. Franco P. Esposti D. Esposti G. Fraschini F. Halberg F. Sothern R.B. Ultradian chronomodulation by melatonin of a Placebo effect upon human killer cell activity. Chronobiologia 1986 13 4 339 343 3816407
    [Google Scholar]
  57. Akbulut K.G. Gönül B. Akbulut H. The effects of melatonin on humoral immune responses of young and aged rats. Pathophysiology 1998 5 5 146 10.1016/S0928‑4680(98)80856‑0
    [Google Scholar]
  58. Kim Y.O. Pyo M.Y. Kim J.H. Influence of melatonin on immunotoxicity of lead. Int. J. Immunopharmacol. 2000 22 10 821 832 10.1016/S0192‑0561(00)00043‑6 10963854
    [Google Scholar]
  59. Deng W.G. Tang S.T. Tseng H.P. Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006 108 2 518 524 10.1182/blood‑2005‑09‑3691 16609073
    [Google Scholar]
  60. Chitimus D.M. Popescu M.R. Voiculescu S.E. Panaitescu A.M. Pavel B. Zagrean L. Zagrean A.M. Melatonin’s impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease. Biomolecules 2020 10 9 1211 10.3390/biom10091211 32825327
    [Google Scholar]
  61. Reiter R.J. Melatonin: Lowering the high price of free radicals. Physiology 2000 15 5 246 250 10.1152/physiologyonline.2000.15.5.246 11390919
    [Google Scholar]
  62. Shukla M. Govitrapong P. Boontem P. Reiter R.J. Satayavivad J. Mechanisms of melatonin in alleviating Alzheimer’s disease. Curr. Neuropharmacol. 2017 15 7 1010 1031 28294066
    [Google Scholar]
  63. Rosales-Corral S.A. Acuña-Castroviejo D. Coto-Montes A. Boga J.A. Manchester L.C. Fuentes-Broto L. Korkmaz A. Ma S. Tan D.X. Reiter R.J. Alzheimer’s disease: Pathological mechanisms and the beneficial role of melatonin. J. Pineal Res. 2012 52 2 167 202 10.1111/j.1600‑079X.2011.00937.x 22107053
    [Google Scholar]
  64. Shi Y. Fang Y.Y. Wei Y.P. Jiang Q. Zeng P. Tang N. Lu Y. Tian Q. Melatonin in synaptic impairments of Alzheimer’s disease. J. Alzheimers Dis. 2018 63 3 911 926 10.3233/JAD‑171178 29710712
    [Google Scholar]
  65. Bubenik G.A. Purtill R.A. Brown G.M. Grota L.J. Melatonin in the retina and the harderian gland. Ontogeny, diurnal variations and melatonin treatment. Exp. Eye Res. 1978 27 3 323 333 10.1016/0014‑4835(78)90166‑5 361425
    [Google Scholar]
  66. Iuvone P.M. Besharse J.C. Dopamine receptor-mediated inhibition of serotonin N-acetyltransferase activity in retina. Brain Res. 1986 369 1-2 168 176 10.1016/0006‑8993(86)90525‑1 3697740
    [Google Scholar]
  67. Tan D.X. Manchester L. Esteban-Zubero E. Zhou Z. Reiter R. Melatonin as a potent and inducible endogenous antioxidant: Synthesis and metabolism. Molecules 2015 20 10 18886 18906 10.3390/molecules201018886 26501252
    [Google Scholar]
  68. Lobo V. Patil A. Phatak A. Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn. Rev. 2010 4 8 118 126 10.4103/0973‑7847.70902 22228951
    [Google Scholar]
  69. Reiter R.J. Tan D. Terron M.P. Flores L.J. Czarnocki Z. Melatonin and its metabolites: New findings regarding their production and their radical scavenging actions. Acta Biochim. Pol. 2007 54 1 1 9 10.18388/abp.2007_3264 17351668
    [Google Scholar]
  70. Kurutas E.B. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: Current state. Nutr. J. 2015 15 1 71 10.1186/s12937‑016‑0186‑5 27456681
    [Google Scholar]
  71. Okatani Y. Wakatsuki A. Kaneda C. Melatonin increases activities of glutathione peroxidase and superoxide dismutase in fetal rat brain. J. Pineal Res. 2000 28 2 89 96 10.1034/j.1600‑079X.2001.280204.x 10709970
    [Google Scholar]
  72. Reiter R.J. Mayo J.C. Tan D.X. Sainz R.M. Alatorre-Jimenez M. Qin L. Melatonin as an antioxidant: Under promises but over delivers. J. Pineal Res. 2016 61 3 253 278 10.1111/jpi.12360 27500468
    [Google Scholar]
  73. Zhang D. Jia X. Lin D. Ma J. Melatonin and ferroptosis: Mechanisms and therapeutic implications. Biochem. Pharmacol. 2023 218 115909 10.1016/j.bcp.2023.115909 37931663
    [Google Scholar]
  74. Wen J. Ariyannur P.S. Ribeiro R. Tanaka M. Moffett J.R. Kirmani B.F. Namboodiri A.M.A. Zhang Y. Efficacy of n-acetylserotonin and melatonin in the eae model of multiple sclerosis. J. Neuroimmune Pharmacol. 2016 11 4 763 773 10.1007/s11481‑016‑9702‑9 27562847
    [Google Scholar]
  75. Reiter R.J. Rosales-Corral S. Tan D.X. Jou M.J. Galano A. Xu B. Melatonin as a mitochondria-targeted antioxidant: One of evolution’s best ideas. Cell. Mol. Life Sci. 2017 74 21 3863 3881 10.1007/s00018‑017‑2609‑7 28864909
    [Google Scholar]
  76. Lerner A.B. Case J.D. Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J. Biol. Chem. 1960 235 7 1992 1997 10.1016/S0021‑9258(18)69351‑2 14415935
    [Google Scholar]
  77. Tan D.X. Hardeland R. Manchester L.C. Paredes S.D. Korkmaz A. Sainz R.M. Mayo J.C. Fuentes-Broto L. Reiter R.J. The changing biological roles of melatonin during evolution: From an antioxidant to signals of darkness, sexual selection and fitness. Biol. Rev. Camb. Philos. Soc. 2010 85 3 607 623 10.1111/j.1469‑185X.2009.00118.x 20039865
    [Google Scholar]
  78. Pelham R.W. A serum melatonin rhythm in chickens and its abolition by pinealectomy. Endocrinology 1975 96 2 543 546 10.1210/endo‑96‑2‑543 1078656
    [Google Scholar]
  79. Tan D.X. Manchester L.C. Terron M.P. Flores L.J. Reiter R.J. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J. Pineal Res. 2007 42 1 28 42 10.1111/j.1600‑079X.2006.00407.x 17198536
    [Google Scholar]
  80. Lewy A.J. Wehr T.A. Goodwin F.K. Newsome D.A. Markey S.P. Light suppresses melatonin secretion in humans. Science 1980 210 4475 1267 1269 10.1126/science.7434030 7434030
    [Google Scholar]
  81. Bernard M. Guerlotté J. Grève P. Gréchez-Cassiau A. Iuvone M.P. Zatz M. Chong N.W. Klein D.C. Voisin P. Melatonin synthesis pathway: Circadian regulation of the genes encoding the key enzymes in the chicken pineal gland and retina. Reprod. Nutr. Dev. 1999 39 3 325 334 10.1051/rnd:19990305 10420435
    [Google Scholar]
  82. Bojkowski C. Aldhous M. English J. Franey C. Poulton A. Skene D. Arendt J. Suppression of nocturnal plasma melatonin and 6-sulphatoxymelatonin by bright and dim light in man. Horm. Metab. Res. 1987 19 9 437 440 10.1055/s‑2007‑1011846 3692439
    [Google Scholar]
  83. Tan D-X. Manchester L.C. Sanchez-Barcelo E. Mediavilla M.D. Reiter R.J. Significance of high levels of endogenous melatonin in Mammalian cerebrospinal fluid and in the central nervous system. Curr. Neuropharmacol. 2010 8 3 162 167 10.2174/157015910792246182 21358967
    [Google Scholar]
  84. Claustrat B. Leston J. Melatonin: Physiological effects in humans. Neurochirurgie 2015 61 2-3 77 84 10.1016/j.neuchi.2015.03.002 25908646
    [Google Scholar]
  85. Bars D.L. Thivolle P. Vitte P.A. Bojkowski C. Chazot G. Arendt J. Frackowiak R.S.J. Claustrat B. PET and plasma pharmacokinetic studies after bolus intravenous administration of [11C]melatonin in humans. Int. J. Rad. Appl. Instrum. B 1991 18 3 357 362 10.1016/0883‑2897(91)90132‑5 2071448
    [Google Scholar]
  86. Pardridge W.M. Mietus L.J. Transport of albumin-bound melatonin through the blood-brain barrier. J. Neurochem. 1980 34 6 1761 1763 10.1111/j.1471‑4159.1980.tb11272.x 7381501
    [Google Scholar]
  87. Ekmekcioglu C. Melatonin receptors in humans: Biological role and clinical relevance. Biomed. Pharmacother. 2006 60 3 97 108 10.1016/j.biopha.2006.01.002 16527442
    [Google Scholar]
  88. Emet M. Ozcan H. Ozel L. Yayla M. Halici Z. Hacimuftuoglu A. A review of melatonin, its receptors and drugs. Eurasian J. Med. 2016 48 2 135 141 10.5152/eurasianjmed.2015.0267 27551178
    [Google Scholar]
  89. Comai S. Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: A novel target in psychopharmacology. J. Psychiatry Neurosci. 2014 39 1 6 21 10.1503/jpn.130009 23971978
    [Google Scholar]
  90. Nosjean O. Ferro M. Cogé F. Beauverger P. Henlin J.M. Lefoulon F. Fauchère J.L. Delagrange P. Canet E. Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000 275 40 31311 31317 10.1074/jbc.M005141200 10913150
    [Google Scholar]
  91. Pandiperumal S. Trakht I. Srinivasan V. Spence D. Maestroni G. Zisapel N. Cardinali D. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008 85 3 335 353 10.1016/j.pneurobio.2008.04.001 18571301
    [Google Scholar]
  92. Carlberg C. Gene regulation by melatonin. Ann. New York Acad. Sci. 2000 917 1 387 396 10.1111/j.1749‑6632.2000.tb05403.x 11268365
    [Google Scholar]
  93. García J.A. Volt H. Venegas C. Doerrier C. Escames G. López L.C. Acuña-Castroviejo D. Disruption of the NF-κB/NLRP3 connection by melatonin requires retinoid-related orphan receptor-α and blocks the septic response in mice. FASEB J. 2015 29 9 3863 3875 10.1096/fj.15‑273656 26045547
    [Google Scholar]
  94. Lardone P.J. Guerrero J.M. Fernández-Santos J.M. Rubio A. Martín-Lacave I. Carrillo-Vico A. Melatonin synthesized by T lymphocytes as a ligand of the retinoic acid-related orphan receptor. J. Pineal Res. 2011 51 4 454 462 10.1111/j.1600‑079X.2011.00909.x 21736617
    [Google Scholar]
  95. Hardeland R. Tan D.X. Reiter R.J. Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines. J. Pineal Res. 2009 47 2 109 126 10.1111/j.1600‑079X.2009.00701.x 19573038
    [Google Scholar]
  96. Tan D.X. Manchester L.C. Burkhardt S. Sainz R.M. Mayo J.C. Kohen R. Shohami E. Huo Y.S. Hardeland R. Reiter R.J. N1 -acetyl- N 2 -formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001 15 12 1 16 10.1096/fj.01‑0309fje 11511530
    [Google Scholar]
  97. Rodriguez C. Mayo J.C. Sainz R.M. Antolín I. Herrera F. Martín V. Reiter R.J. Regulation of antioxidant enzymes: A significant role for melatonin. J. Pineal Res. 2004 36 1 1 9 10.1046/j.1600‑079X.2003.00092.x 14675124
    [Google Scholar]
  98. Rosales-Corral S. Tan D.X. Reiter R.J. Valdivia-Velázquez M. Martínez-Barboza G. Pablo Acosta-Martínez J. Ortiz G.G. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid- β peptide in rat brain: A comparative, in vivo study versus vitamin C and E. J. Pineal Res. 2003 35 2 80 84 10.1034/j.1600‑079X.2003.00057.x 12887649
    [Google Scholar]
  99. Wu H.J. Wu C. Niu H.J. Wang K. Mo L.J. Shao A.W. Dixon B.J. Zhang J.M. Yang S.X. Wang Y.R. Neuroprotective mechanisms of melatonin in hemorrhagic stroke. Cell. Mol. Neurobiol. 2017 37 7 1173 1185 10.1007/s10571‑017‑0461‑9 28132129
    [Google Scholar]
  100. Feng D. Wang B. Wang L. Abraham N. Tao K. Huang L. Shi W. Dong Y. Qu Y. Pre-ischemia melatonin treatment alleviated acute neuronal injury after ischemic stroke by inhibiting endoplasmic reticulum stress-dependent autophagy via PERK and IRE 1 signalings. J. Pineal Res. 2017 62 3 12395 10.1111/jpi.12395 28178380
    [Google Scholar]
  101. Álvarez-Sánchez N. Cruz-Chamorro I. Díaz-Sánchez M. Lardone P.J. Guerrero J.M. Carrillo-Vico A. Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients. Sci. Rep. 2019 9 1 2302 10.1038/s41598‑019‑38897‑w 30783191
    [Google Scholar]
  102. Winthorst W.H. Roest A.M. Bos E.H. Meesters Y. Penninx B.W.J.H. Nolen W.A. de Jonge P. Self-attributed seasonality of mood and behavior: A report from the Netherlands study of depression and anxiety. Depress. Anxiety 2014 31 6 517 523 10.1002/da.22130 23695951
    [Google Scholar]
  103. Claustrat B. Brun J. Geoffriau M. Zaidan R. Mallo C. Chazot G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997 17 4 511 517 10.1046/j.1468‑2982.1997.1704511.x 9209772
    [Google Scholar]
  104. Reiter R.J. The pineal gland and melatonin in relation to aging: A summary of the theories and of the data. Exp. Gerontol. 1995 30 3-4 199 212 10.1016/0531‑5565(94)00045‑5 7556503
    [Google Scholar]
  105. Reiter R.J. Tan D.X. Poeggeler B. Menendez-Pelaez A. Chen L.D. Saarela S. Melatonin as a free radical scavenger: Implications for aging and age-related diseases. Ann. New York Acad. Sci. 1994 719 1 1 12 10.1111/j.1749‑6632.1994.tb56817.x 8010585
    [Google Scholar]
  106. Reiter R.J. Tan D. Sainz R.M. Mayo J.C. Lopez-Burillo S. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 2002 54 10 1299 1321 10.1211/002235702760345374 12396291
    [Google Scholar]
  107. Weishaupt J.H. Bartels C. Pölking E. Dietrich J. Rohde G. Poeggeler B. Mertens N. Sperling S. Bohn M. Hüther G. Schneider A. Bach A. Sirén A.L. Hardeland R. Bähr M. Nave K.A. Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006 41 4 313 323 10.1111/j.1600‑079X.2006.00377.x 17014688
    [Google Scholar]
  108. Singhal N.K. Srivastava G. Patel D.K. Jain S.K. Singh M.P. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. J. Pineal Res. 2011 50 2 97 109 10.1111/j.1600‑079X.2010.00819.x 20964710
    [Google Scholar]
  109. Li S.X. Liu L.J. Xu L.Z. Gao L. Wang X.F. Zhang J.T. Lu L. Diurnal alterations in circadian genes and peptides in major depressive disorder before and after escitalopram treatment. Psychoneuroendocrinology 2013 38 11 2789 2799 10.1016/j.psyneuen.2013.07.009 24001941
    [Google Scholar]
  110. Rajaratnam S.M.W. Polymeropoulos M.H. Fisher D.M. Roth T. Scott C. Birznieks G. Klerman E.B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet 2009 373 9662 482 491 10.1016/S0140‑6736(08)61812‑7 19054552
    [Google Scholar]
  111. Adamczyk-Sowa M. Pierzchala K. Sowa P. Polaniak R. Kukla M. Hartel M. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients. J. Physiol. Pharmacol. 2014 65 4 543 550 25179086
    [Google Scholar]
  112. Emens J. Lewy A. Kinzie J.M. Arntz D. Rough J. Circadian misalignment in major depressive disorder. Psychiatry Res. 2009 168 3 259 261 10.1016/j.psychres.2009.04.009 19524304
    [Google Scholar]
  113. Tchekalarova J. Nenchovska Z. Atanasova D. Atanasova M. Kortenska L. Stefanova M. Alova L. Lazarov N. Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats. Behav. Brain Res. 2016 302 11 28 10.1016/j.bbr.2015.12.043 26779670
    [Google Scholar]
  114. Papp M. Gruca P. Boyer P.A. Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003 28 4 694 703 10.1038/sj.npp.1300091 12655314
    [Google Scholar]
  115. Sheline Y.I. Wang P.W. Gado M.H. Csernansky J.G. Vannier M.W. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA 1996 93 9 3908 3913 10.1073/pnas.93.9.3908 8632988
    [Google Scholar]
  116. Gómez-Florit M. Ramis J.M. Monjo M. Anti-fibrotic and anti-inflammatory properties of melatonin on human gingival fibroblasts in vitro. Biochem. Pharmacol. 2013 86 12 1784 1790 10.1016/j.bcp.2013.10.009 24144630
    [Google Scholar]
  117. Álvarez-Sánchez N. Cruz-Chamorro I. Díaz-Sánchez M. Sarmiento-Soto H. Medrano-Campillo P. Martínez-López A. Lardone P.J. Guerrero J.M. Carrillo-Vico A. Melatonin reduces inflammatory response in peripheral T helper lymphocytes from relapsing-remitting multiple sclerosis patients. J. Pineal Res. 2017 63 4 12442 10.1111/jpi.12442 28793364
    [Google Scholar]
  118. Damrongrungruang T. Panpitakkul P. Somudorn J. Sangchart P. Mahakunakorn P. Uthaiwat P. Daduang J. Panyatip P. Puthongking P. Priprem A. Glutaryl melatonin niosome gel for topical oral mucositis: Anti-inflammatory and anticandidiasis. Curr. Drug Deliv. 2020 17 3 195 206 10.2174/1567201817666200122162545 31969103
    [Google Scholar]
  119. Maldonado M.D. Moreno H. Calvo J.R. Melatonin present in beer contributes to increase the levels of melatonin and antioxidant capacity of the human serum. Clin. Nutr. 2009 28 2 188 191 10.1016/j.clnu.2009.02.001 19249143
    [Google Scholar]
  120. Yosefifard M. Vaezi G. Malekirad A.A. Faraji F. Hojati V. A randomized control trial study to determine the effect of melatonin on serum levels of IL-1β and TNF-α in patients with multiple sclerosis. Iran. J. Allergy Asthma Immunol. 2019 18 6 649 654 32245308
    [Google Scholar]
  121. Sánchez-López A.L. Ortiz G.G. Pacheco-Moises F.P. Mireles-Ramírez M.A. Bitzer-Quintero O.K. Delgado-Lara D.L.C. Ramírez-Jirano L.J. Velázquez-Brizuela I.E. Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis. Arch. Med. Res. 2018 49 6 391 398 10.1016/j.arcmed.2018.12.004 30595364
    [Google Scholar]
  122. Adamczyk-Sowa M. Sowa P. Mucha S. Zostawa J. Mazur B. Owczarek M. Pierzchała K. Changes in serum ceruloplasmin levels based on immunomodulatory treatments and melatonin supplementation in multiple sclerosis patients. Med. Sci. Monit. 2016 22 2484 2491 10.12659/MSM.895702 27420299
    [Google Scholar]
  123. Adamczyk-Sowa M. Sowa P. Adamczyk J. Niedziela N. Misiolek H. Owczarek M. Zwirska-Korczala K. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. J. Physiol. Pharmacol. 2016 67 2 235 242
    [Google Scholar]
  124. Roostaei T. Sahraian M.A. Hajeaghaee S. Gholipour T. Togha M. Siroos B. Mansouri S. Mohammadshirazi Z. Aghazadeh Alasti M. Harirchian M.H. Impact of melatonin on motor, cognitive and neuroimaging indices in patients with multiple sclerosis. Iran. J. Allergy Asthma Immunol. 2015 14 6 589 595 26725556
    [Google Scholar]
  125. Liu X. Wang Y. Yang J. Liu Y. Zhou D. Hou M. Xiang L. Anti-edema effect of melatonin on spinal cord injury in rats. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2015 159 2 220 226 10.5507/bp.2015.012 25916278
    [Google Scholar]
  126. Liu J.B. Tang T.S. Yang H.L. Xiao D.S. Antioxidation of melatonin against spinal cord injury in rats. Chin. Med. J. 2004 117 4 571 575 15109452
    [Google Scholar]
  127. Park S. Lee S.K. Park K. Lee Y. Hong Y. Lee S. Jeon J.C. Kim J.H. Lee S.R. Chang K.T. Hong Y. Beneficial effects of endogenous and exogenous melatonin on neural reconstruction and functional recovery in an animal model of spinal cord injury. J. Pineal Res. 2012 52 1 107 119 10.1111/j.1600‑079X.2011.00925.x 21854445
    [Google Scholar]
  128. Gao Y. Bai C. Zheng D. Li C. Zhang W. Li M. Guan W. Ma Y. Combination of melatonin and Wnt-4 promotes neural cell differentiation in bovine amniotic epithelial cells and recovery from spinal cord injury. J. Pineal Res. 2016 60 3 303 312 10.1111/jpi.12311 26762966
    [Google Scholar]
  129. Kaptanoglu E. Tuncel M. Palaoglu S. Konan A. Demirpençe E. Kilinç K. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury. J. Neurosurg. 2000 93 1 77 84 10879762
    [Google Scholar]
  130. Erol F.S. Kaplan M. Tiftikci M. Yakar H. Ozercan I. Ilhan N. Topsakal C. Comparison of the effects of octreotide and melatonin in preventing nerve injury in rats with experimental spinal cord injury. J. Clin. Neurosci. 2008 15 7 784 790 10.1016/j.jocn.2007.06.009
    [Google Scholar]
  131. Gül Ş. Çelik S.E. Kalaycı M. Taşyürekli M. Çokar N. Bilge T. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. Surg. Neurol. 2005 64 4 355 361 10.1016/j.surneu.2005.03.036 16231427
    [Google Scholar]
  132. Cayli S.R. Kocak A. Yilmaz U. Tekiner A. Erbil M. Ozturk C. Batcioglu K. Yologlu S. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury. Eur. Spine. J. 2004 13 8 724 732 10.1007/s00586‑003‑0550‑y 2004
    [Google Scholar]
  133. Genovese T. Mazzon E. Crisafulli C. Esposito E. Di Paola R. Muià C. Di Bella P. Bramanti P. Cuzzocrea S. Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. J. Pineal Res. 2007 43 2 140 153 10.1111/j.1600‑079X.2007.00454.x 17645692
    [Google Scholar]
  134. Oyar E. Korkmaz A. Kardeş O. Omeroğlu S. Effects of melatonin on ischemic spinal cord injury caused by aortic cross clamping in rabbits. Curr. Neurovasc. Res. 2008 5 1 46 51 10.2174/156720208783565681 18289021
    [Google Scholar]
  135. Krityakiarana W. Sompup K. Jongkamonwiwat N. Mukda S. Pinilla F.G. Govitrapong P. Phansuwan-Pujito P. Effects of melatonin on severe crush spinal cord injury–induced reactive astrocyte and scar formation. J. Neurosci. Res. 2016 94 12 1451 1459 10.1002/jnr.23930 27717042
    [Google Scholar]
  136. Naeimi A. Zaminy A. Amini N. Balabandi R. Golipoor Z. Effects of melatonin-pretreated adipose-derived mesenchymal stem cells (MSC) in an animal model of spinal cord injury. BMC Neurosci. 2022 23 1 65 10.1186/s12868‑022‑00752‑6 36384473
    [Google Scholar]
  137. Topsakal C. Kilic N. Ozveren F. Akdemir I. Kaplan M. Tiftikci M. Gursu F. Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Spine 2003 28 15 1643 1652 10.1097/01.BRS.0000083163.03910.B1 12897486
    [Google Scholar]
  138. Hong Y. Jin Y. Park K. Choi J. Kang H. Lee S.R. Hong Y. Elevated serum melatonin under constant darkness enhances neural repair in spinal cord injury through regulation of circadian clock proteins expression. J. Clin. Med. 2019 8 2 135 10.3390/jcm8020135 30678072
    [Google Scholar]
  139. Xu G. Shi D. Zhi Z. Ao R. Yu B. Melatonin ameliorates spinal cord injury by suppressing the activation of inflammasomes in rats. J. Cell. Biochem. 2019 120 4 5183 5192 10.1002/jcb.27794 30257055
    [Google Scholar]
  140. Samantaray S. Sribnick E.A. Das A. Knaryan V.H. Matzelle D.D. Yallapragada A.V. Reiter R.J. Ray S.K. Banik N.L. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J. Pineal Res. 2008 44 4 348 357 10.1111/j.1600‑079X.2007.00534.x 18086148
    [Google Scholar]
  141. Wang H. Wang H. Huang H. Qu Z. Ma D. Dang X. Dong Q. Melatonin attenuates spinal cord injury in mice by activating the Nrf2/ARE signaling pathway to inhibit the NLRP3 inflammasome. Cells 2022 11 18 2809 10.3390/cells11182809 36139384
    [Google Scholar]
  142. Li Y. Guo Y. Fan Y. Tian H. Li K. Mei X. Melatonin enhances autophagy and reduces apoptosis to promote locomotor recovery in spinal cord injury via the pi3k/akt/mtor signaling pathway. Neurochem. Res. 2019 44 8 2007 2019 10.1007/s11064‑019‑02838‑w 31325156
    [Google Scholar]
  143. Yang Z. Bao Y. Chen W. He Y. Melatonin exerts neuroprotective effects by attenuating astro- and microgliosis and suppressing inflammatory response following spinal cord injury. Neuropeptides 2020 79 102002 10.1016/j.npep.2019.102002 31902595
    [Google Scholar]
  144. Yan L. Han X. Zhang M. Kou H. Liu H. Cheng T. Melatonin exerts neuroprotective effects in mice with spinal cord injury by activating the Nrf2/Keap1 signaling pathway via the MT2 receptor. Exp. Ther. Med. 2023 27 1 37 10.3892/etm.2023.12325 38125360
    [Google Scholar]
  145. Piao M.S. Lee J.K. Jang J.W. Hur H. Lee S.S. Xiao L. Kim H.S. Melatonin improves functional outcome via inhibition of matrix metalloproteinases-9 after photothrombotic spinal cord injury in rats. Acta Neurochir. 2014 156 11 2173 2182 10.1007/s00701‑014‑2119‑4 24879621
    [Google Scholar]
  146. Zhang Y. Liu Z. Zhang W. Wu Q. Zhang Y. Liu Y. Guan Y. Chen X. Melatonin improves functional recovery in female rats after acute spinal cord injury by modulating polarization of spinal microglial/macrophages. J. Neurosci. Res. 2019 97 7 733 743 10.1002/jnr.24409 31006904
    [Google Scholar]
  147. Shen Z. Zhou Z. Gao S. Guo Y. Gao K. Wang H. Dang X. Melatonin inhibits neural cell apoptosis and promotes locomotor recovery via activation of the wnt/β-catenin signaling pathway after spinal cord injury. Neurochem. Res. 2017 42 8 2336 2343 10.1007/s11064‑017‑2251‑7 28417262
    [Google Scholar]
  148. Song H. Yu W. Liu X. Ma X. Improved probiotic viability in stress environments with post-culture of alginate–chitosan microencapsulated low density cells. Carbohydr. Polym. 2014 108 10 16 10.1016/j.carbpol.2014.02.084 24751241
    [Google Scholar]
  149. Jing Y. Bai F. Chen H. Dong H. Melatonin prevents blood vessel loss and neurological impairment induced by spinal cord injury in rats. J. Spinal Cord Med. 2017 40 2 222 229 10.1080/10790268.2016.1227912 27735218
    [Google Scholar]
  150. Zhong G. Yang Y. Feng D. Wei K. Chen J. Chen J. Deng C. Melatonin protects injured spinal cord neurons from apoptosis by inhibiting mitochondrial damage via the SIRT1/Drp1 signaling pathway. Neuroscience 2023 534 54 65 10.1016/j.neuroscience.2023.10.010 37865165
    [Google Scholar]
  151. Esposito E. Genovese T. Caminiti R. Bramanti P. Meli R. Cuzzocrea S. Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J. Pineal Res. 2009 46 1 79 86 10.1111/j.1600‑079X.2008.00633.x 19090911
    [Google Scholar]
  152. Esposito E. Genovese T. Caminiti R. Bramanti P. Meli R. Cuzzocrea S. Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury. J. Pineal Res. 2008 45 2 149 156 10.1111/j.1600‑079X.2008.00569.x 18298463
    [Google Scholar]
  153. Bi J. Sun P. Feng E. Shen J. Chen C. Tan H. Li Z. Lin Y. Melatonin synergizes with methylprednisolone to ameliorate acute spinal cord injury. Front. Pharmacol. 2022 12 723913 10.3389/fphar.2021.723913 35095480
    [Google Scholar]
  154. Wu Q. Jing Y. Yuan X. Zhang X. Li B. Liu M. Wang B. Li H. Liu S. Xiu R. Melatonin treatment protects against acute spinal cord injury-induced disruption of blood spinal cord barrier in mice. J. Mol. Neurosci. 2014 54 4 714 722 10.1007/s12031‑014‑0430‑4
    [Google Scholar]
  155. Fee D.B. Swartz K.R. Scheff N. Roberts K. Gabbita P. Scheff S. Melatonin-analog, β-methyl-6-chloromelatonin, supplementation in spinal cord injury. Brain Res. 2010 1340 81 85 10.1016/j.brainres.2010.04.047 20420812
    [Google Scholar]
  156. Jing Y. Wu Q. Yuan X. Li B. Liu M. Zhang X. Liu S. Li H. Xiu R. Microvascular protective role of pericytes in melatonin-treated spinal cord injury in the C57BL/6 mice. Chin. Med. J. 2014 127 15 2808 2813 25146619
    [Google Scholar]
  157. Gao K. Niu J. Dang X. Neuroprotection of melatonin on spinal cord injury by activating autophagy and inhibiting apoptosis via SIRT1/AMPK signaling pathway. Biotechnol. Lett. 2020 42 10 2059 2069 10.1007/s10529‑020‑02939‑5 32514788
    [Google Scholar]
  158. Fujimoto T. Nakamura T. Ikeda T. Takagi K. Potent protective effects of melatonin on experimental spinal cord injury. Spine 2000 25 7 769 775 10.1097/00007632‑200004010‑00003 10751286
    [Google Scholar]
  159. Erten S.F. Kocak A. Ozdemir I. Aydemir S. Colak A. Reeder B.S. Protective effect of melatonin on experimental spinal cord ischemia. Spinal Cord 2003 41 10 533 538 10.1038/sj.sc.3101508 14504608
    [Google Scholar]
  160. Bi J. Shen J. Chen C. Li Z. Tan H. Sun P. Lin Y. Role of melatonin in the dynamics of acute spinal cord injury in rats. J. Cell. Mol. Med. 2021 25 6 2909 2917 10.1111/jcmm.16325 33497543
    [Google Scholar]
  161. Park K. Lee Y. Park S. Lee S. Hong Y. Kil Lee S. Hong Y. Synergistic effect of melatonin on exercise-induced neuronal reconstruction and functional recovery in a spinal cord injury animal model. J. Pineal Res. 2010 48 3 270 281 10.1111/j.1600‑079X.2010.00751.x 20210855
    [Google Scholar]
  162. Kalkan E. Çiçek O. Ünlü A. Abuşoǧlu S. Kalkan S.S. Avunduk M.C. Baysefer A. The effects of prophylactic zinc and melatonin application on experimental spinal cord ischemia–reperfusion injury in rabbits: Experimental study. Spinal Cord 2007 45 11 722 730 10.1038/sj.sc.3102035 17297496
    [Google Scholar]
  163. Majidpoor J. Khezri Z. Rostamzadeh P. Mortezaee K. Rezaie M.J. Fathi F. Abouzaripour M. Bariki M.G. Moradi F. Shirazi R. Joghataei M.T. The expressions of NLRP1, NLRP3, and AIM2 inflammasome complexes in the contusive spinal cord injury rat model and their responses to hormonal therapy. Cell Tissue Res. 2020 381 3 397 410 10.1007/s00441‑020‑03250‑5 32696217
    [Google Scholar]
  164. Rainer Q. Xia L. Guilloux J.P. Gabriel C. Mocaër E. Hen R. Enhamre E. Gardier A.M. David D.J. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int. J. Neuropsychopharmacol. 2012 15 3 321 335 10.1017/S1461145711000356 21473810
    [Google Scholar]
  165. Ali T. Hao Q. Ullah N. Rahman S.U. Shah F.A. He K. Zheng C. Li W. Murtaza I. Li Y. Jiang Y. Tan Z. Li S. Melatonin act as an antidepressant via attenuation of neuroinflammation by targeting sirt1/Nrf2/HO-1 signaling. Front. Mol. Neurosci. 2020 13 96 10.3389/fnmol.2020.00096 32595452
    [Google Scholar]
  166. Domínguez-López S. Mahar I. Bambico F.R. Labonté B. Ochoa-Sánchez R. Leyton M. Gobbi G. Short-term effects of melatonin and pinealectomy on serotonergic neuronal activity across the light–dark cycle. J. Psychopharmacol. 2012 26 6 830 844 10.1177/0269881111408460 21730015
    [Google Scholar]
  167. Ruksee N. Tongjaroenbuangam W. Mahanam T. Govitrapong P. Melatonin pretreatment prevented the effect of dexamethasone negative alterations on behavior and hippocampal neurogenesis in the mouse brain. J. Steroid Biochem. Mol. Biol. 2014 143 72 80 10.1016/j.jsbmb.2014.02.011 24589478
    [Google Scholar]
  168. Jand Y. Ghahremani M.H. Ghanbari A. Ejtemaei-Mehr S. Guillemin G.J. Ghazi-Khansari M. Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. Sci. Rep. 2022 12 1 15963 10.1038/s41598‑022‑20164‑0 36153399
    [Google Scholar]
  169. Ghareghani M. Zibara K. Sadeghi H. Farhadi N. Spasticity treatment ameliorates the efficacy of melatonin therapy in experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Cell. Mol. Neurobiol. 2018 38 5 1145 1151 10.1007/s10571‑018‑0580‑y 29497878
    [Google Scholar]
  170. Di Paolo C. Reverte I. Colomina M.T. Domingo J.L. Gómez M. Chronic exposure to aluminum and melatonin through the diet: Neurobehavioral effects in a transgenic mouse model of Alzheimer disease. Food. Chem. Toxicol. 2014 69 320 329 10.1016/j.fct.2014.04.022
    [Google Scholar]
  171. Otalora B.B. Popovic N. Gambini J. Popovic M. Viña J. Bonet-Costa V. Reiter R.J. Camello P.J. Rol M.Á. Madrid J.A. Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: Effects of melatonin or ramelteon. Chronobiol. Int. 2012 29 7 822 834 10.3109/07420528.2012.699119 22823866
    [Google Scholar]
  172. Jürgenson M. Zharkovskaja T. Noortoots A. Morozova M. Beniashvili A. Zapolski M. Zharkovsky A. Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer’s disease. J. Pharm. Pharmacol. 2019 71 11 1695 1705 10.1111/jphp.13165 31531878
    [Google Scholar]
  173. Andrade M.K. Souza L.C. Azevedo E.M. Bail E.L. Zanata S.M. Andreatini R. Vital M.A.B.F. Melatonin reduces β-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer’s disease model. IBRO Neurosci. Rep. 2023 14 264 272 10.1016/j.ibneur.2023.01.005 36926592
    [Google Scholar]
  174. Olcese J.M. Cao C. Mori T. Mamcarz M.B. Maxwell A. Runfeldt M.J. Wang L. Zhang C. Lin X. Zhang G. Arendash G.W. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J. Pineal Res. 2009 47 1 82 96 10.1111/j.1600‑079X.2009.00692.x 19538338
    [Google Scholar]
  175. Zhang Y. Cook A. Kim J. Baranov S.V. Jiang J. Smith K. Cormier K. Bennett E. Browser R.P. Day A.L. Carlisle D.L. Ferrante R.J. Wang X. Friedlander R.M. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013 55 26 35 10.1016/j.nbd.2013.03.008 23537713
    [Google Scholar]
  176. Abo Taleb H.A. Alghamdi B.S. Neuroprotective effects of melatonin during demyelination and remyelination stages in a mouse model of multiple sclerosis. J. Mol. Neurosci. 2020 70 3 386 402 10.1007/s12031‑019‑01425‑6
    [Google Scholar]
  177. Dardiotis E. Panayiotou E. Feldman M.L. Hadjisavvas A. Malas S. Vonta I. Hadjigeorgiou G. Kyriakou K. Kyriakides T. Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neurosci. Lett. 2013 548 170 175 10.1016/j.neulet.2013.05.058 23748038
    [Google Scholar]
  178. He F. Chou C.J. Scheiner M. Poeta E. Chen Y. N.; Gunesch, S.; Hoffmann, M.; Sotriffer, C.; Monti, B.; Maurice, T., Melatonin-and ferulic acid-based HDAC6 selective inhibitors exhibit pronounced immunomodulatory effects in vitro and neuroprotective effects in a pharmacological Alzheimer’s disease mouse model. J. Med. Chem. 2021 64 7 3794 3812 10.1021/acs.jmedchem.0c01940 33769811
    [Google Scholar]
  179. Ozansoy M. Ozansoy M.B. Yulug B. Cankaya S. Kilic E. Goktekin S. Kilic U. Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model. J. Clin. Neurosci. 2020 73 237 244 10.1016/j.jocn.2019.11.046 32061493
    [Google Scholar]
  180. Özşimşek A. Övey İ.S. Potential effects of melatonin on TRPA1 channels in the prevention and treatment of Alzheimer’s disease. Noro Psikiyatri Arsivi 2022 59 3 188 192 36160083
    [Google Scholar]
  181. Buendia I. Egea J. Parada E. Navarro E. León R. Rodríguez-Franco M.I. López M.G. The melatonin-N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer’s model via hemo-oxygenase-1 induction. ACS Chem. Neurosci. 2015 6 2 288 296 10.1021/cn5002073 25393881
    [Google Scholar]
  182. Hornedo-Ortega R. Da Costa G. Cerezo A.B. Troncoso A.M. Richard T. Garcia-Parrilla M.C. In vitro effects of serotonin, melatonin, and other related indole compounds on amyloid-β kinetics and neuroprotection. Mol. Nutr. Food Res. 2018 62 3 1700383 10.1002/mnfr.201700383 29131485
    [Google Scholar]
  183. Gurer-Orhan H. Karaaslan C. Ozcan S. Firuzi O. Tavakkoli M. Saso L. Suzen S. Novel indole-based melatonin analogues: Evaluation of antioxidant activity and protective effect against amyloid β-induced damage. Bioorg. Med. Chem. 2016 24 8 1658 1664 10.1016/j.bmc.2016.02.039 26970662
    [Google Scholar]
  184. Buendia I. Navarro E. Michalska P. Gameiro I. Egea J. Abril S. López A. González-Lafuente L. López M.G. León R. New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection. Future Med. Chem. 2015 7 15 1961 1969 10.4155/fmc.15.99 26496465
    [Google Scholar]
  185. López-Iglesias B. Pérez C. Morales-García J.A. Alonso-Gil S. Pérez-Castillo A. Romero A. López M.G. Villarroya M. Conde S. Rodríguez-Franco M.I. New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer’s disease. J. Med. Chem. 2014 57 9 3773 3785 10.1021/jm5000613 24738476
    [Google Scholar]
  186. Buendia I. Parada E. Navarro E. León R. Negredo P. Egea J. López M.G. Subthreshold concentrations of melatonin and galantamine improves pathological ad-hallmarks in hippocampal organotypic cultures. Mol. Neurobiol. 2016 53 5 3338 3348 10.1007/s12035‑015‑9272‑5 26081146
    [Google Scholar]
  187. Zheng R. Ruan Y. Yan Y. Lin Z. Xue N. Yan Y. Tian J. Yin X. Pu J. Zhang B. Melatonin attenuates neuroinflammation by down-regulating NLRP3 inflammasome via a SIRT1-dependent pathway in MPTP-induced models of Parkinson’s disease. J. Inflamm. Res. 2021 14 3063 3075 10.2147/JIR.S317672 34267535
    [Google Scholar]
  188. Mayo J.C. Sainz R.M. Uria H. Antolin I. Esteban M.M. Rodriguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: Implications for Parkinson’s disease. J. Pineal Res. 1998 24 3 179 192 10.1111/j.1600‑079X.1998.tb00531.x 9551855
    [Google Scholar]
  189. Li J. Liu H. Wang X. Xia Y. Huang J. Wang T. Lin Z. Xiong N. Melatonin ameliorates Parkinson’s disease via regulating microglia polarization in a RORα-dependent pathway. NPJ Parkinsons Dis. 2022 8 1 90 10.1038/s41531‑022‑00352‑5
    [Google Scholar]
  190. Huang J.Y. Hong Y.T. Chuang J.I. Fibroblast growth factor 9 prevents MPP + -induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro. J. Neurochem. 2009 109 5 1400 1412 10.1111/j.1471‑4159.2009.06061.x 19476551
    [Google Scholar]
  191. Alvira D. Tajes M. Verdaguer E. Acuña-Castroviejo D. Folch J. Camins A. Pallas M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson’s disease. J. Pineal Res. 2006 40 3 251 258 10.1111/j.1600‑079X.2005.00308.x 16499562
    [Google Scholar]
  192. Chuang J.I. Chen T.H. Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP + treatment in human astrocytoma U373MG cells. J. Pineal Res. 2004 36 2 117 125 10.1046/j.1600‑079X.2003.00107.x 14962063
    [Google Scholar]
  193. Zampol M.A. Barros M.H. Melatonin improves survival and respiratory activity of yeast cells challenged by alpha-synuclein and menadione. Yeast 2018 35 3 281 290 10.1002/yea.3296 29143358
    [Google Scholar]
  194. Emamgholipour S. Hossein-nezhad A. Sahraian M.A. Askarisadr F. Ansari M. Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes. Life Sci. 2016 145 34 41 10.1016/j.lfs.2015.12.014 26679105
    [Google Scholar]
  195. Tajes M. Gutierrez-Cuesta J. Ortuño-Sahagun D. Camins A. Pallàs M. Anti-aging properties of melatonin in an in vitro murine senescence model: Involvement of the sirtuin 1 pathway. J. Pineal Res. 2009 47 3 228 237 10.1111/j.1600‑079X.2009.00706.x 19650880
    [Google Scholar]
  196. Wang X. Sirianni A. Pei Z. Cormier K. Smith K. Jiang J. Zhou S. Wang H. Zhao R. Yano H. Kim J.E. Li W. Kristal B.S. Ferrante R.J. Friedlander R.M. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J. Neurosci. 2011 31 41 14496 14507 10.1523/JNEUROSCI.3059‑11.2011 21994366
    [Google Scholar]
  197. Su L.Y. Li H. Lv L. Feng Y.M. Li G.D. Luo R. Zhou H.J. Lei X.G. Ma L. Li J.L. Xu L. Hu X.T. Yao Y.G. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation. Autophagy 2015 11 10 1745 1759 10.1080/15548627.2015.1082020 26292069
    [Google Scholar]
  198. Megha K.B. Arathi A. Shikha S. Alka R. Ramya P. Mohanan P.V. Significance of melatonin in the regulation of circadian rhythms and disease management. Mol. Neurobiol. 2024 61 8 5541 5571 10.1007/s12035‑024‑03915‑0 38206471
    [Google Scholar]
  199. Muñoz-Jurado A. Escribano B.M. Caballero-Villarraso J. Galván A. Agüera E. Santamaría A. Túnez I. Melatonin and multiple sclerosis: Antioxidant, anti-inflammatory and immunomodulator mechanism of action. Inflammopharmacology 2022 30 5 1569 1596 10.1007/s10787‑022‑01011‑0 35665873
    [Google Scholar]
  200. Alamdari A.F. Rahnemayan S. Rajabi H. Vahed N. Kashani H.R.K. Rezabakhsh A. Sanaie S. Melatonin as a promising modulator of aging related neurodegenerative disorders: Role of microRNAs. Pharmacol. Res. 2021 173 105839 10.1016/j.phrs.2021.105839 34418564
    [Google Scholar]
  201. Potes Y. Cachán-Vega C. Antuña E. García-González C. Menéndez-Coto N. Boga J.A. Gutiérrez-Rodríguez J. Bermúdez M. Sierra V. Vega-Naredo I. Coto-Montes A. Caballero B. Benefits of the neurogenic potential of melatonin for treating neurological and neuropsychiatric disorders. Int. J. Mol. Sci. 2023 24 5 4803 10.3390/ijms24054803 36902233
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673416300251023052701
Loading
Melatonin: Novel Insights in the Treatment of Neurodegenerative Diseases
Bentham Science Publishers ; https://doi.org/10.2174/0109298673416300251023052701
/content/journals/cmc/10.2174/0109298673416300251023052701
/content/journals/cmc/10.2174/0109298673416300251023052701
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: oxidative stress ; novel therapeutic approach ; inflammation ; Melatonin ; cellular signalling pathways ; neurodegenerative diseases

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test